Simoons M L
Academisch Ziekenhuis Rotterdam-Dijkzigt, Thoraxcentrum, Dr. Molewaterplein 40, 3015 GD Rotterdam.
Ned Tijdschr Geneeskd. 2000 Dec 16;144(51):2442-4.
The recent report on lipid lowering therapy from the Netherlands Health Council is largely in agreement with the 1998 guidelines made at the Dutch Institute for Health Care Improvement CBO on the same topic. In addition to advice for a healthy life style and no smoking, lipid lowering therapy (particularly statins) is recommended in: patients with familial hyperlipidaemia; patients with atherosclerotic disease and a total cholesterol > 5.0 mmol/l; patients with diabetes and multiple risk factors including a total cholesterol > 5.0 mmol/l; other persons with markedly increased risk for development of coronary artery disease. The report does not dwell upon implementation and effects of the recommendations or on the question what preventive efforts are desirable for persons without manifest cardiovascular disease. In practice, prescribing the recommended medication is more successful than attempts to change the life style. The effects of multifactorial life style intervention may be considerable, however. The high social costs of cholesterol-lowering treatment should be regarded as an investment in health.
荷兰健康委员会最近发布的关于降脂治疗的报告,在很大程度上与荷兰医疗保健改善研究所(CBO)1998年就同一主题制定的指南一致。除了建议保持健康的生活方式和戒烟外,还建议在以下人群中进行降脂治疗(特别是他汀类药物):家族性高脂血症患者;患有动脉粥样硬化疾病且总胆固醇>5.0 mmol/L的患者;患有糖尿病且有多种危险因素(包括总胆固醇>5.0 mmol/L)的患者;其他患冠状动脉疾病风险明显增加的人。该报告没有详述这些建议的实施情况和效果,也没有提及对于没有明显心血管疾病的人应采取何种预防措施的问题。在实践中,开具推荐药物比试图改变生活方式更成功。然而,多因素生活方式干预的效果可能相当可观。降低胆固醇治疗的高昂社会成本应被视为对健康的一种投资。